samedan logo

 
 
spacer
home > pmps > autumn 2003 > drug delivery: an evolving concept
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Drug Delivery: An Evolving Concept

The concept of drug delivery is evolving to go far beyond its original focus of finding alternative modes of administration in order to reduce drug side effects and prolong drug action over time. Pharmaceutical and biotechnology companies are now exploiting a variety of new technologies and novel approaches to drug delivery, using delivery concepts to develop high-value, differentiated products. These drug delivery applications are increasingly considered an integral part of the development process - one that not only offers strategies to expand product pipelines and extend product and patent life, but is also critical to the development of superior and, in some cases, breakthrough therapies.

The concept of drug delivery was born in the early 1970s. As originally conceived, drug delivery applications focused principally on finding alternative modes of administration - notably transdermal patch and oral sustained release formulations - in order to reduce drug side effects and prolong the action of drugs over time. Since then, however, the field of drug delivery has evolved into an array of technologies that provide new routes of administration or extended performance for both novel and established pharmaceuticals. Pharmaceutical companies have increasingly used drug delivery technologies to enhance the competitiveness of their products, addressing strategic business goals as well as goals focused on improved drug performance:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Christopher Searcy, Vice President of Corporate Development at Nektar Therapeutics

Christopher J Searcy, Pharm D, is Vice President of Corporate Development at Nektar Therapeutics (Inhale). He joined the company from GalaGen Inc, in Minnesota, where he was Vice President of Business Development. From 1985 to 1995, he held various positions at Pfizer Inc in registration and regulatory affairs, clinical research and marketing. His last position at Pfizer was Director, Licensing and Development. He holds a Master of Business Administration from the University of Pennsylvania, Wharton School, and a Pharm D from the University of Minnesota.

spacer
Christopher J Searcy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG appoints Rafael Costa as Vice President Sales for the Americas Region

ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce the appointment of Rafael Costa as Vice President for the Americas region.
More info >>

White Papers

Clinical Trial Labelling More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement